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Aims: Cardiac hypertrophy is associated with the increase of total amount of RNA, which is in accordance with
RNA polymerase II (RNAPII) activation via C-terminal domain (CTD) phosphorylation of the largest subunit of
RNAPII. It has been demonstrated that endothelin-1 (ET-1) phosphorylates CTD at the hypertrophic response
in cardiomyocytes. However, it is unclearwhether ET-1-induced hypertrophy is affected by the CTDphosphatase,
transcription factor IIF-interacting CTD phosphatase1 (FCP1).
Mainmethods:We analyzed whether ET-1-induced cardiomyocyte hypertrophy was affected by overexpression
of FCP1 or dominant-negative form of FCP1 (dnFCP1) in neonatal rat cardiomyocytes.
Key ﬁndings: The level of ET-1-induced RNAPII CTD phosphorylation was decreased by FCP1 overexpression,
whereas it was sustained by dnFCP1. Global RNA synthesis evaluated by [3H]-uridine incorporation showed
that the ET-1-induced increase in RNA synthesis was suppressed by FCP1 and was augmented by dnFCP1. ET-1-
induced increase in cell surface area was suppressed by FCP1 and was preserved by dnFCP1. Furthermore, the
ET-1-induced increase in molecular markers of cardiac hypertrophy, expression of ANP and β-MHC gene, was
suppressed by FCP1 and was not inhibited by dnFCP1.
Signiﬁcance: ET-1-induced cardiac hypertrophy and CTDphosphorylation level are functionally regulated by FCP1.
These ﬁndings suggest that FCP1 plays an important role in ET-1-induced cardiac hypertrophy via controlling
phosphorylation level of the RNAPII CTD.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Cardiac hypertrophy, which is deﬁned by an increase in heart size
and/or myoﬁbrillar volume without a change in myocyte number, is
the characteristic response to several stimuli including mechanical
stress, growth-promoting agents, and signaling proteins (Sadoshima
and Izumo, 1997), which are common situations in clinical settings,
because increasing wall thickness ameliorates mechanical wall stress
(Frey and Olson, 2003). Meanwhile, increased ventricular mass is an
independent risk factor for cardiovascular mortality in humans (Levy
et al., 1990); thus, suppression of hypertrophy might be beneﬁcial to
the prognosis (Molkentin and Dorn, 2001; Adams et al., 1998).
Cardiomyocyte hypertrophy is associated with an increase in global
RNA and protein levels. One clue, involving translational control, is the
activation of p70 S6 kinase, which phosphorylates the ribosomal S6
protein (Shioi et al., 2002). A second mechanism is a global increase in+81 29 853 3143.
-NC-ND license.RNA content per cell (Olson and Schneider, 2003). Sano et al. reported
that cardiac growth is likely to be governed by transcription elongation
(Sano et al., 2002, 2004). Phosphorylation of RNA polymerase II
(RNAPII) in its carboxyl-terminal domain (CTD), which comprises 52
repeats of an evolutionally conserved serine-rich heptapeptide,
YSPTSPS, is a critical, essential mediator of messenger RNA production
(Dahmus, 1996). We have shown that CTD is phosphorylated as a
consequence of diverse hypertrophic stimuli (pressure overload and
the small G-protein Gαq in vivo) and that both principal CTD kinases—
cyclin-dependent kinase (Cdk)7 and Cdk9—are activated in chronic
hypertrophy (Sano et al., 2002) during the transition from transcript
initiation to transcript elongation. After the termination of transcript
elongation, phosphorylated CTD is dephosphorylated by the CTD
phosphatase FCP1 (transcription factor IIF-interacting CTD phosphatase
1) and inactivated RNAPII is recruited to the initiation site (Cho et al.,
1999; Kamada et al., 2003). However, there are less data concerning
the inactivation of RNAPII by phosphatases on RNA synthesis, rather
than the activation of RNAPII by CTD kinases.
Endothelin (ET)-1, a potent vasoconstrictive peptide produced
by endothelial cells (Yanagisawa et al., 1988), is also produced by
cardiomyocytes and contributes to the development of cardiac
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We have reported that the production of ET-1 is markedly increased
in the failing hearts of rats with chronic heart failure (Sakai et al.,
1996a,b) and that the enhancement of myocardial ET-1 contributes
to the modulation of cardiac function (Sakai et al., 1996a) and
cardiac hypertrophy from the molecular level in the failing hearts
(Sakai et al., 2000); moreover, chronic administration of the ETA
receptor antagonist BQ-123 inhibited the cardiac remodeling and
ameliorated cardiac function (Sakai et al., 1996b).
ET-1 is shown to phosphorylate CTD of RNAPII (Sano et al., 2002),
suggesting that ET-1 participates in the pathological hypertrophy
partly via the activation of RNAPII. However, there are no data how
the dephosphorylation of CTD by FCP1 affects ET-1-induced CTD
activation and hypertrophy. We studied in cultured cardiomyocytes
whether ET-1-induced CTD phosphorylation and hypertrophy is
affected by overexpression of FCP1 or dominant-negative form of
FCP1 (dnFCP1) in neonatal rat cardiomyocytes; and we tried to clarify
the regulatory function of FCP1 on ET-1-inducing cardiac growth.
Materials and methods
Adenovirus vectors
Human FCP1 cDNA and dnFCP1, which was created by mutagenesis
at the DXDX motif of phosphatase domain by D188A and D190A, was
ligated to pShuttle plasmid; adenoviral vector was created by AdEasy
Adenoviral Vector System (Stratagene, La Jolla, CA) and the CMV
promoter drove the introduced gene. Recombinant adenoviral plasmids
were digested by Pac I, transfected to 293 cells and ampliﬁed, andﬁnally
puriﬁed by Vivaspin column system (Sartorius Stadium Biotechnology,
Goettingen, Germany).
Cardiomyocyte culture and morphological evaluation
Ventricular cardiac myocytes were isolated from 2- to 3-day-old
Sprague–Dawley rats, as described previously (Shimojo et al., 2007),
and were incubated on ﬁbronectin-coated dishes in DMEM-Ham's
F-12 medium supplemented with 0.1% fatty acid-free bovine serum
albumin (BSA) (Sigma, St. Louis, MO) in 95% air-5% CO2. Cells were
cultured for 2 days after differential adhesion and then used for
further experiments. Myocytes were transfected with adenovirus
for Lac Z, FCP1, and dnFCP1 at the titer of 20 multiplicity of infection
(MOI). Enhanced green ﬂuorescent protein (EGFP) was simultaneously
transfected in the experiment to visualizing the morphology of
cardiomyocytes. 24 h after transfection, vehicle or ET-1 (10−7 M in ﬁnal
concentration) was applied to culture medium. 24 h later, EGFP-labeled
cardiomyocytes were observed by microscope (BX-8100, Keyence,
Tokyo, Japan). The surface area of cardiomyocytes for 10 cells/ﬁeld by 5
ﬁelds in each group was evaluated by BZ-II measurement module
(Keyence, Tokyo, Japan). Animal experiments were carried out in a
humane manner after we received approval from the Institutional
Animal Experiment Committee of the University of Tsukuba and were
in accordance with the Regulation for Animal Experiments in our
university.
RNA and protein synthetic rate
Rates of RNA and protein synthesis in cultured neonatal rat
cardiomyocytes were assessed by measuring [3H]-uridine or [3H]-
phenylalanine incorporation into acid-insoluble cellular materials
as described previously (Sano et al., 2002; Shimojo et al., 2007).
The cells were plated on 24-well dishes at a density of 105 cells/well
and transfected with adenovirus for Lac Z, FCP1, and dnFCP1. After
treatment with ET-1 or vehicle for 24 h, 0.1 mCi/ml [3H]-uridine or
[3H]-phenylalanine (GE Healthcare, Piscataway, NJ) was added andcells were incubated for 24 h. The cells were washed twice with cold
PBS, and 5% trichloroacetic acid was added for 10 min. The cells were
then incubated with 0.25% trypsin at 37 °C for 30 min, and cell
residues were solubilized in 0.5 M NaOH for 10 min. Aliquots were
counted with a scintillation counter (LS-6500 scintillation counter;
Beckman Coulter, Fullerton, CA).Western blot
2×106 cardiomyocyteswereplated on60-mmdishes and transfected
with adenovirus for Lac Z, FCP1, and dnFCP. 24 h after transfection,
cardiomyocytes were treated with ET-1, incubated for 15 min, and
sampled, because CTD of RNAPII is maximally phosphorylated at
this point (Sano et al., 2002). Cardiomyocytes of each group were
lysed on ice with buffer (10 mM Tris HCl, 150 mM NaCl, 1 mM
ethylenediamine‐N, N, N′, N′-tetraacetic acid [EDTA], 0.1% sodium
dodecyl sulfate [SDS]), as described previously (Shimojo et al., 2007).
The protein concentration of supernatant was determined with the
bicinchoninic acid protein assay (Pierce, Rockford, IL). Samples were
run on SDS-polyacrylamide gel electrophoresis (PAGE), using 5%–
10% gradient or 10% polyacrylamide gels, and electrotransferred to
nitrocellulose ﬁlter membrane. To reduce nonspeciﬁc binding, the
membrane was blocked for 1 h at room temperature with 5% BSA
or skim milk in tris-buffered saline (TBS) containing 0.1% Tween 20
(TBST). Thereafter, the membrane was incubated overnight at 4 °C
with primary antibodies. After washing 3 times with TBST, we
incubated the membrane with horseradish peroxidase-conjugated
rabbit anti-mouse or goat anti-rabbit antibody (Life Technologies,
Grand Island, NY; Cell Signaling Technology, Danvers, MA) at 1:10,000
in TBST at room temperature for 60 min. The blots were visualized with
an enhanced chemiluminescence detection system (GE Healthcare),
captured by CCD camera system (AE-6981, Atto Corporation, Tokyo,
Japan) or exposed to X-ray ﬁlm, and analyzed by CS Analyzer (Atto
Corporation). The followings were used as ﬁrst antibodies: mouse
anti-phosphorylated CTD of RNA polymerase II monoclonal antibody
(H14), which recognizes the phosphoserine 5 (Covance, Emeryville,
CA), rabbit anti-total CTD of RNA polymerase II (4H8) (Cell signaling),
rabbit anti-FCP1 (Bethyl, Montgomery, TX), and mouse anti-actin
antibody (Sigma-Aldrich, St. Louis, MO).Gene expression analysis
1×106 cardiomyocytes were plated on 6-well plate and transfected
with adenovirus for Lac Z, FCP1, and dnFCP1. Cardiomyocytes were
treated with ET-1 or vehicle for 24 h. Total RNA from cardiomyocytes
was isolated using RNeasy (Qiagen, Valencia, CA). After isolation,
DNase I treatment, and quantiﬁcation, RNA was reverse transcribed
to cDNA by a synthesis kit (Qiagen). The reaction was performed at
37 °C for 60 min. The mRNA expression levels of target genes were
analyzed by real-time quantitative PCR with TaqMan probe using an
ABI Prism 7700 sequence detector (AppliedBiosystems, Foster, CA), as
described previously (Shimojo et al., 2007). The commercially available
gene-speciﬁc primers and TaqMan probe sets were obtained from
AppliedBiosystems. The expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA was used as an internal control. The
PCR mixture (25 μl total volume) consisted of forward and reverse
primers for each gene at 450 nM each, FAM-labeled primer probes at
200 nM, and TaqMan Universal PCR Master Mix (AppliedBiosystems).
PCR ampliﬁcation was performed in duplicate as follows: 1 cycle at
95 °C for 10 min and 40 cycles at 94 °C for 15 s and 60 °C for 1 min.
The quantitative values of target mRNA were normalized by GAPDH
mRNA expression. Primers and probes sets are as follows: atrial
natriuretic peptide (ANP), Rn00561661_m1; beta-myosin heavy chain
(β-MHC), Rn00568328_m1; and GAPDH, Rn01775763_g1.
574 S. Sakai et al. / Life Sciences 91 (2012) 572–577Statistical analysis
Values are shown as means±SD. Data were compared by one-
way ANOVA with Turkey–Kramer's HSD using the statistical software
JMP ver 8.0 (SAS Institute, Cary, NC). Differences were considered
signiﬁcant at Pb0.05.
Results
RNAPII CTD phosphorylation
As shown in Fig. 1A, Western blot showed that FCP1 or dnFCP1
protein, the molecular size of both are same, was effectively
overexpressed by the gene delivery using adenoviruses. We used ET-1A
B
Fig. 1. Effects of FCP1 and dnFCP1 on ET-1-induced RNAPII CTD phosphorylation in the
cardiomyocytes. A. Representative Western blots showing protein expression of
phosphorylated CTD of RNAPII, total CTD, and FCP1 or dnFCP1 in vehicle or ET-1 treated
cardiomyocyte, which were transfected with Lac Z (control), FCP1, and dnFCP1. Actin
was used as an internal loading control. B. Bar graph represents the ratio in the blot
intensity of phosphorylated CTD to total RNAPII CTD. Lac Z or FCP1, dnFCP1 transfected
cardiomyocytes were incubated with vehicle or ET-1 for 15 min. Data are analyzed by
one-way ANOVA and expressed as the mean±SD of 3 separate experiments. ⁎Pb0.05,
⁎⁎Pb0.01, compared to LacZ without ET-1 treatment. ##Pb0.01, compared to LacZ with
ET-1 treatment.as a representative agent for the hypertrophy, because ET-1 is a potent
hypertrophic activity exerting from lower concentration rather than
angiotensin II. ET-1 signiﬁcantly phosphorylated CTD, indicating that
ET-1 activated RNAPII. The ET-1-induced CTD phosphorylation was
signiﬁcantly inhibited by FCP1 overexpression, whereas dnFCP1
overexpression did not affect CTD phosphorylation level (Fig. 1A
and B). These results suggest that RNAPII is activated by ET-1 and that
the gain or loss of FCP1 function affects the CTD phosphorylation level.Global RNA and protein synthesis
ET-1 signiﬁcantly increased global RNA synthesis estimated by [3H]-
uridine incorporation by 1.8-folds in cardiomyocytes. ET-1-induced
RNA synthesis was signiﬁcantly inhibited by FCP1 overexpression,
whereas it was markedly augmented by dnFCP1 (3.6-fold); moreover,
themagnitude of RNA synthesiswith dnFCP1 treatmentwas signiﬁcantly
higher than that of stimulation only by ET-1 alone (Fig. 2A). Data of global
protein synthesis estimated by [3H]-phenylalanine incorporation showed
the similar tendency with global RNA synthesis; ET-1 signiﬁcantly
increased the protein synthesis (1.5-folds), FCP1 signiﬁcantly inhibited
the increase stimulated by ET-1, conversely, dnFCP1 augmented the
increase by 2.2-fold (Fig. 2B). These results suggest that the gain or
loss of FCP1 function determines the RNA and protein synthesis level
probably via altering the RNAPII activation level.Cardiomyocyte hypertrophy and hypertrophic markers
There are many works (Ito, 1997; Sadoshima and Izumo, 1997;
Molkentin and Dorn, 2001; Frey and Olson, 2003; Olson and
Schneider, 2003,), in which the fetal gene program is mobilized when
the cardiomyocyte develops hypertrophy (hypertrophy-associated
genes, such as ANP and β-MHC) both in in vitro and in vivo in addition
to the morphological changes (the increase of cell size). ET-1
signiﬁcantly increased the cell surface area in cardiomyocytes (Fig.
3A–E). The increase of ET-1-induced increase of cardiomyocyte surface
area was signiﬁcantly inhibited by FCP1 overexpression, whereas
the increased cell size was preserved by dnFCP1 overexpression (Fig.
3A–E). These results suggest that gain of FCP1 function suppressed
the ET-1-induced cardiac hypertrophy partly via the inhibition of
RNAPII activation.
ANP gene expression was signiﬁcantly augmented in ET-1-treated
cardiomyocytes by 1.4-fold. Under the ET-1 treatment, FCP1 signiﬁcantly
inhibited the ANP expression, whereas dnFCP1 did not affect ANP
augmentation (Fig. 4A). The expression pattern of β-MHC gene showed
the similar tendency to that of ANP (Fig. 4B). These ﬁndings suggest that
the cardiomyocyte hypertrophy induced by ET-1 is affected by gain or
loss of FCP1 function, which is revealed by the molecular markers for
cardiac hypertrophy, ANP and β-MHC.
Taken together, in the process of the ET-1-evoked cardiomyocyte
hypertrophy, FCP1 may negatively regulate the cardiomyocyte
hypertrophy altering the RNAPII CTD phosphorylation level.Discussion
In the present study, ET-1 augmented RNAPII CTD phosphorylation
level, which was decreased by FCP1 overexpression and was abolished
by dnFCP1. Global RNA and protein synthesis showed that the ET-1-
induced increases were suppressed by FCP1 and were augmented by
dnFCP1. Furthermore, the ET-1-induced cardiomyocyte hypertrophy
was suppressed by FCP1 but not by dnFCP1, which was in accordance
with the alteration of the molecular markers for hypertrophy,
expression of ANP and β-MHC gene. These ﬁndings suggest that FCP1
is one of key regulators of ET-1-induced cardiomyocyte hypertrophy
BA
Fig. 2. Effects of FCP1 and dnFCP1 on the ET-1-induced global RNA and protein synthesis. Bar graphs represent global RNA synthesis estimated by [3H]-uridine incorporation (A) and
global protein synthesis estimated by [3H]-phenylalanine incorporation (B). Lac Z or FCP1, dnFCP1 transfected cardiomyocytes were incubated with vehicle or ET-1 for 24 h. Data
are analyzed by one-way ANOVA and expressed as the mean±SD. 6 wells of radioactivity in each group were measured. ⁎Pb0.05, ⁎⁎Pb0.01, compared to LacZ without ET-1
treatment. ##Pb0.01, compared to LacZ with ET-1 treatment.
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phosphorylation level.
Cardiomyocyte hypertrophy and CTD phosphorylation
ET-1 has a cell proliferative/hypertrophic activity in many kinds
of cells (Miyauchi and Masaki, 1999; Takuwa et al., 1989), in which
genes positively related to the cell growth are enhanced as one of
responses to the stimuli; thus, it suggests that RNAPII may be
activated and may increase the transcription of the genes involved
in series of the process. Actually, ET-1 increased CTD phosphorylation
level in cardiomyocytes in this study, which data were supported
by other researcher (Sano et al., 2002). Another hypertrophic agents
such as phenylephrine, heparin-binding epidermal growth factor
(HB-EGF) also increased the phosphorylated CTD level (Sano et al.,
2002), suggesting that the phosphorylation of CTD may be a general
phenomenon at cardiomyocyte hypertrophy. Although we do not
have data of angiotensin II (Ang II) on cardiomyocyte growth, another
agent for hypertrophy, it is anticipated that Ang II would also induce
the phosphorylation of CTD, and this is also expected by the data
of increased CTD phosphorylation level in the cardio-speciﬁcally
overexpressed mice of Gαq, which the type 1 Ang II receptor couples
with.
Effects of CTD dephosphorylation on cardiomyocyte hypertrophy
It is well known that ET-1 contributes to cardiac hypertrophy and
heart failure. Use of ET receptor antagonists prevents development
and progression of heart failure. There is no evidence from those studies
on the expression and regulation of RNA polymerase II and FCP1. In
the present study, we showed the regulatory function of FCP1 on ET-
1-induced CTD phosphorylation and cardiomyocyte hypertrophy. Our
data elucidating that the inhibition of CTD phosphorylation by FCP1
suppressed cardiomyocyte hypertrophy are novel ﬁndings. Because,
there are no reports how the dephosphorylation of CTD by FCP1 affects
the cardiomyocyte growth, although Cho et al. showed that wild type of
fcp1 decreased the phosphorylated formof CTD in the yeast, butmutant
fcp1 did not affect (Cho et al., 2001). It suggests that the cardiomyocyteenlargement elicited by ET-1 is partly controlled by FCP1 through the
negative regulation of the RNAPII CTD phosphorylation level. There are
no reports concerning the effect of FCP1 on cardiomyocyte hypertrophy
induced by other hypertrophic agents including Ang II. Moreover, it
is unclear whether the potency of hypertrophic activity of each agent
is inﬂuenced by FCP1. Further study will be needed to elucidate these
points.
As is mentioned above, Cdk7 and Cdk9 regulate the CTD
phosphorylation, which are involved in the transcript elongation. FCP1
contributes to the dephosphorylation both in Ser5 and Ser2 of the CTD
in mammalian cells (Lin et al., 2002). Recently, another phosphatase
of FCP1 family, small CTD phosphatase1 (SCP1), has been isolated
(Yeo et al., 2003). FCP1 dephosphorylated the CTD of RNAPII in the
present study; however, it is unclear which of phosphatases mainly
contributes to the dephosphorylation of CTDand thenegative regulation
of cardiomyocyte hypertrophy.The discrepancy in pattern between the global synthesis of RNA and
protein and the extent of CTD phosphorylation level and hypertrophy
marker expression
Among the ET-1-treated cardiomyocytes, the magnitude in global
synthesis of RNA and protein measured by [3H]-uridine and [3H]-
phenylalanine incorporation, respectively, was signiﬁcantly suppressed
by FCP1 transfection and was signiﬁcantly augmented by dnFCP1
compared to LacZ transfected with ET-1-treated group. However,
concerning to the expression of phosphorylated CTD, the gene
expression of hypertrophy markers (ANP and β-MHC), and the cell
surface area, it was not signiﬁcant between the dnFCP1 transfected
with ET-1-treated group and LacZ with ET-1 group, although there
was a tendency of increase in dnFCP with ET-1 group compared to
only ET-1-treated group. We suppose the reason for the discrepancy
as followings: 1, the pattern of hypertrophy marker gene expression
differs from that of global RNA synthesis; 2, the cell surface area does
not reﬂect the whole cell volume and protein amount; 3, both the
post-transcriptional and post-translational modiﬁcation affects the
results; 4, the sensitivity of distinguishing the differences differs
A B
C D
E
Fig. 3. Representative morphology of the ET-1 (10−7 M)-induced cardiomyocyte hypertrophy affected by the transfection of FCP1 and dnFCP1. Adenovirus was used for the gene
delivery. A. Cardiomyocyte transfected with LacZ (control) and vehicle treatment; B. LacZ transfection and ET-1 treatment; C. FCP1 transfection and ET-1 treatment; and D. dnFCP1
transfection and ET-1 treatment. Bar represents 50 μm. E. Bar graph shows the cell surface area in each group. Lac Z or FCP1, dnFCP1 transfected cardiomyocytes were incubated
with vehicle or ET-1 for 24 h. The surface area of cardiomyocytes for 10 cells/ﬁeld by 5 ﬁelds in each group was evaluated. Data are analyzed by one-way ANOVA and expressed
as mean±SD. ⁎Pb0.05, ⁎⁎Pb0.01, compared to LacZ transfection without ET-1 treatment. ##Pb0.01, compared to LacZ with ET-1 treatment.
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mechanisms occur in the discrepancies.Conclusion
We demonstrated the regulatory function of FCP1 on the ET-1-
induced cardiomyocyte hypertrophy for the ﬁrst time. ET-1-induced
cardiomyocyte hypertrophy may be associated with the increase of
CTD phosphorylation level; FCP1 may be a negative regulator of
CTD phosphorylation and affect the hypertrophic activity of ET-1. It
suggests that FCP1 is one of key regulators of the cardiomyocytehypertrophy to determine suitable cardiomyocyte size by controlling
the RNAPII CTD phosphorylation level.
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